spartalizumab
spartalizumab: 4 clinical trials tracked.
spartalizumab evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about spartalizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (4)
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
Primary endpoint: Frequency and nature of AE and SAE by subject
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
Primary endpoint: Percentage of subjects who proceed to radical nephrectomy